Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Pure red-cell aplasia and recombinant erythropoietin.

× No keyword cloud information.

16 in total

1. Micelle-associated protein in epoetin formulations: aA risk factor for immunogenicity?

Authors: Suzanne Hermeling; Huub Schellekens; Daan J A Crommelin; Wim Jiskoot
Journal: Pharm Res Date: 2003-12 Impact factor: 4.200

Review 2. Structure-immunogenicity relationships of therapeutic proteins.

Authors: Suzanne Hermeling; Daan J A Crommelin; Huub Schellekens; Wim Jiskoot
Journal: Pharm Res Date: 2004-06 Impact factor: 4.200

Review 3. Current methods for detecting antibodies against erythropoietin and other recombinant proteins.

Authors: Robin Thorpe; Steven J Swanson
Journal: Clin Diagn Lab Immunol Date: 2005-01

Review 4. Emerging erythropoiesis-stimulating agents.

Authors: Robert N Foley
Journal: Nat Rev Nephrol Date: 2010-02-23 Impact factor: 28.314

5. Association of Erythropoietin Dose and Route of Administration with Clinical Outcomes for Patients on Hemodialysis in the United States.

Authors: Daniel G Wright; Elizabeth C Wright; Andrew S Narva; Constance T Noguchi; Paul W Eggers
Journal: Clin J Am Soc Nephrol Date: 2015-09-10 Impact factor: 8.237

Review 6. Differentiating factors between erythropoiesis-stimulating agents: a guide to selection for anaemia of chronic kidney disease.

Authors: Robert Deicher; Walter H Hörl
Journal: Drugs Date: 2004 Impact factor: 9.546

Review 7. Understanding the immunogenicity and antigenicity of nanomaterials: Past, present and future.

Authors: Anna N Ilinskaya; Marina A Dobrovolskaia
Journal: Toxicol Appl Pharmacol Date: 2016-01-07 Impact factor: 4.219

Review 8. Recombinant erythropoietin in clinical practice.

Authors: T Ng; G Marx; T Littlewood; I Macdougall
Journal: Postgrad Med J Date: 2003-07 Impact factor: 2.401

Review 9. Management options for cancer therapy-related anaemia.

Authors: Tim J Littlewood
Journal: Drug Saf Date: 2002 Impact factor: 5.606

Review 10. Epoetin-associated pure red cell aplasia: past, present, and future considerations.

Authors: June M McKoy; Robin E Stonecash; Denis Cournoyer; Jerome Rossert; Allen R Nissenson; Dennis W Raisch; Nicole Casadevall; Charles L Bennett
Journal: Transfusion Date: 2008-05-14 Impact factor: 3.157